IDEAYA Biosciences Announces Upcoming Investor Events for 2025

Author: Thomas Cooper Updated: 10-27-2025 06:13 AM

IDEAYA Biosciences' Upcoming Investor Engagements

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a dedicated precision medicine oncology company known for its innovative work in targeted therapeutics, is set to participate in significant investor relations events. With a focus on advancing cancer treatment, IDEAYA’s participation in these events highlights its commitment to transparency and engagement with investors.

Details of the Investor Events

The firm will be involved in two notable engagements this fall, allowing stakeholders to gain valuable insights into ongoing projects and the company's vision.

Citi's 2025 SMID Cap Biopharma Call Series

This event is scheduled for Thursday, November 6, 2025, at 12:00 PM ET. During this invitation-only forum, Yujiro S. Hata, President and Chief Executive Officer of IDEAYA, will engage in a fireside chat. He will be hosted by Yigal D. Nochomovitz, Ph.D., who serves as the Director for SMid Cap Biotech Analysts.

Jefferies Global Healthcare Conference in London

The second event will take place on Tuesday, November 18, 2025, at 1:00 PM GMT / 8:00 AM ET. This conference will also feature Yujiro S. Hata in a fireside chat, facilitated by Maury Raycroft, Ph.D., an Equity Research Analyst specializing in Biotechnology.

Accessing Live Coverage of the Events

For those interested in following along, a live audio webcast of both engagements will be available in the 'Investors/Events' section of the IDEAYA website. Replays of the webcasts will also be accessible for a period of 30 days after each event concludes, providing an opportunity for those unable to attend live to catch up on the discussions.

About IDEAYA Biosciences

IDEAYA Biosciences is revolutionizing cancer treatment through precision medicine. The company is dedicated to discovering, developing, and commercializing transformative therapies. By fusing small-molecule drug discovery with in-depth structural biology and bioinformatics, IDEAYA is equipped to pioneer targeted therapies that address the unique genetic drivers of various cancers.

With a robust pipeline focused on synthetic lethality and antibody-drug conjugates (ADCs), IDEAYA aims to redefine the landscape of oncology treatments, ensuring they are more personalized and effective. The mission is clear: to change the trajectory of cancer therapy and improve outcomes for patients, making every treatment as effective as possible.

Frequently Asked Questions

What is IDEAYA Biosciences focused on?

IDEAYA Biosciences primarily focuses on the discovery and development of targeted therapeutics in the field of precision medicine for cancer treatment.

When are the upcoming investor events?

The upcoming investor events are scheduled for November 6 and November 18, 2025.

Who will represent IDEAYA at these events?

Yujiro S. Hata, the President and Chief Executive Officer, will represent IDEAYA at both investor events.

Will there be live coverage of the events?

Yes, a live audio webcast of each event will be available on the IDEAYA website.

How long will the webcast replays be available?

Replays of the webcasts will be accessible for 30 days following each live event.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.